Hsieh, P.-L.; Chu, P.-M.; Cheng, H.-C.; Huang, Y.-T.; Chou, W.-C.; Tsai, K.-L.; Chan, S.-H.
Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. Int. J. Mol. Sci. 2022, 23, 10146.
https://doi.org/10.3390/ijms231710146
AMA Style
Hsieh P-L, Chu P-M, Cheng H-C, Huang Y-T, Chou W-C, Tsai K-L, Chan S-H.
Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences. 2022; 23(17):10146.
https://doi.org/10.3390/ijms231710146
Chicago/Turabian Style
Hsieh, Pei-Ling, Pei-Ming Chu, Hui-Ching Cheng, Yu-Ting Huang, Wan-Ching Chou, Kun-Ling Tsai, and Shih-Hung Chan.
2022. "Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation" International Journal of Molecular Sciences 23, no. 17: 10146.
https://doi.org/10.3390/ijms231710146
APA Style
Hsieh, P.-L., Chu, P.-M., Cheng, H.-C., Huang, Y.-T., Chou, W.-C., Tsai, K.-L., & Chan, S.-H.
(2022). Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. International Journal of Molecular Sciences, 23(17), 10146.
https://doi.org/10.3390/ijms231710146
